CG Oncology CGON 深 沪
已收盘 10-02 16:00:00 美东时间
67.38
-0.970
-1.42%
华盛通- 最 高69.73
- 今 开69.35
- 成交量 154.11万股
- 最 低 66.61
- 昨 收 68.35
- 总市值 59.73亿
- 52周最高 80.97
- 市盈率 静 --
- 换手率 1.74%
- 52周最低 35.80
- 委 比 -11.70%
- 总股本 8864.04万
- 历史最高 80.97
- 量 比 1.23
- 振 幅 4.56%
- 历史最低 14.80
- 每 手 1
- 风险率 12.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.
08-07 21:12
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-07 05:20
财报速睇 | CG Oncology 2026财年Q2营收0.01亿美元，同比增长（去年同期为零）；归母净利润亏损0.79亿美元，同比亏损扩大90.8%
华盛资讯8月6日讯，CG Oncology公布2026财年Q2业绩，公司Q2营收0.01亿美元，同比增长（去年同期为零），归母净利润亏损0.79亿美元，同比亏损扩大90.8%。
08-06 21:25
财报速睇 | CG Oncology 2026财年Q2营收0.01亿美元，同比增长；归母净利润亏损0.79亿美元，同比亏损扩大90.8%
华盛资讯8月6日讯，CG Oncology公布2026财年Q2业绩，公司Q2营收0.01亿美元，同比增长，归母净利润亏损0.79亿美元，同比亏损扩大90.8%。
08-06 20:54
CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 66.67 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $1.157 million w...
08-06 20:53
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
CG Oncology announced the publication of pivotal Phase 3 BOND-003 Cohort C trial results in *The Lancet Oncology*, showing cretostimogene grenadenorepvec monotherapy achieved 75.5% complete response rates in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. With a median duration of response of 27.9 months, 89% of patients maintained bladder preservation at 12 months and 81% at 24 months. The treatment demonstrated ...
07-27 22:45
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware Supreme Court and continue to seek to recover the value ...
07-17 04:38
ANI Pharmaceuticals Reveals Trial Court Denied Company’s Motion For A New Trial And Judgment As A Matter Of Law For Unjust Enrichment; Co. Intends To Appeal Rulings To The Delaware Supreme Court And Continue To Seek To Recover The Value Of The Assets It Sold To CG Oncology In 2010
Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010 PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE)...
07-17 04:38
Wolfe Research Initiates Coverage On CG Oncology with Peer Perform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on CG Oncology (NASDAQ:CGON) with a Peer Perform rating.
05-19 20:11
